Back to News
Market Impact: 0.3
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Source: zacks.com
Corporate EarningsHealthcare & BiotechCompany FundamentalsBanking & Liquidity
Intellia Therapeutics’ Q3 loss deepened, while progress in its lonvo-z and nex-z clinical programs supported its pipeline outlook. A $400 million loan facility adds financial flexibility; the article provides no loss amount or clinical milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
NTLA0.20
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens